Treatment of menopausal symptoms with hormone therapy. The treatment of menopausal symptoms with MHT. Efficacy, Safety, and Tolerability of Low- Dose Hormone Therapy in Managing Menopausal Symptoms. ACOG practice bulletin. Clinical management. Number 5. 0, January 2. Obstet Gynecol. 20. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Women's Health Initiative randomized controlled trial. Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal. Menostar Patch, a very-low-dose estrogen patch, is now FDA approved for prevention of bone loss in postmenopausal women. Efficacy, Safety, and Tolerability of Low-Dose Hormone. JAMA2. 00. 2; 2. 88: 3. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. Women's Health Initiative randomized controlled trial. JAMA2. 00. 4; 2. 91: 1. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years. JAMA2. 00. 7; 2. 97: 1. Effect of estrogen plus progestin on stroke in postmenopausal women. An estrogen patch therapy could help reduce the risk of developing Alzheimer's disease among postmenopausal women. Findings suggest that an earlier hormone replacement treatment could be an effective preventive intervention. Estrogen patches, used as hormone therapy for newly postmenopausal women, could cut the risk of Alzheimer's disease, according to an American study published in the Journal of Alzheimer's Disease. This new study could. The Women's Health Initiative: a randomized trial. JAMA2. 00. 3; 2. 89: 2. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2. 00. 4; 2. 92: 1. Influence of estrogen plus progestin on breast cancer and mammography in healthy. Estradiol Patch official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and. This Committee Opinion provides guidelines for prescribing postmenopausal estrogen therapy and hormone therapy and evaluating the risk of venous thromboembolism. Indicated for the prevention of postmenopausal osteoporosis, Minivelle. The world's smallest estrogen therapy patch My Minivelle. Women's Health Initiative randomized trial. JAMA2. 00. 3; 2. 89: 3. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative. Maturitas. 20. 06; 5. Chlebowski RT, Wactawski- Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the. Women's Health Initiative randomized trial. JAMA2. 00. 3; 2. 90: 1. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 20. Ritenbaugh C, Stanford JL, Wu L, et al. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's. Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening. JAMA2. 00. 6; 2. 95: 1. Lower doses of oral estrogen and progestogens as treatment for postmenopausal women. Semin Reprod Med. Rationale for use of lower estrogen doses for postmenopausal hormone therapy. Maturitas. 20. 07; 5. Hormone therapy and coronary heart disease: the role of time since menopause and age. J Womens Health. 20. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2. Maturitas. 20. 05; 5. Estrogen and progestogen use in peri- and postmenopausal women: March 2. The North American Menopause Society. Menopause. 20. 07; 1. Endometrial effects of lower doses of conjugated equine estrogens and. Fertil Steril. 20. Endometrial effects of lower doses of conjugated equine estrogens and. Fertil Steril. 20. Historical perspectives in postmenopausal hormone therapy: defining the right dose and duration. Mayo Clin Proc. 20. Lowest effective transdermal 1. Obstet Gynecol. 20. Diem S, Grady D, Quan J, et al. Effects of ultralow- dose transdermal estradiol on postmenopausal symptoms in women aged 6. Menopause. 20. 06; 1. Low- dose esterified estrogens (0. Climacteric. 20. 00; 3: 1. Relief of vasomotor symptoms and vaginal atrophy with lower doses. Fertil Steril. 20. Utian WH, Burry KA, Archer DF, et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system. Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. Am J Obstet Gynecol. Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB, Rowan JP. Efficacy and local tolerance of a low- dose, 7- day matrix. Obstet Gynecol. 19. Pt 1): 5. 87–9. 2. Ultra- low- dose estradiol and norethisterone acetate: effective menopausal. Climacteric. 20. 07; 1. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 1. Menopause. 20. 00; 7: 3. Speroff L, Symons J, Kempfert N, Rowan J. The effect of varying low- dose combinations of norethindrone acetate and ethinyl. Femhrt) on the frequency and intensity of vasomotor symptoms. Menopause. 20. 00; 7: 3. Gadomska H, Barcz E, Cyganek A, Leocmach Y, Chadha- Boreham H, Marianowski L. Efficacy and tolerability of low- dose transdermal. Oesclim) in the treatment of menopausal symptoms. Curr Med Res Opin. Uterine and vaginal effects of unopposed ultralow- dose transdermal. Obstetricians Gynecol. Premarin (conjugated estrogens tablets, USP) product information. Philadelphia, PA: Wyeth Pharmaceuticals. Pharmacia & Upjohn Company Estring (estradiol vaginal ring 2 mg) product information. New York, NY: Pharmacia & Upjohn Company. Vagifem (estradiol vaginal tablets 2. Princeton, NJ: Novo Nordisk Inc., 2. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women. The North American Menopause Society. Menopause. 20. 07; 1. Pt 1): 3. 55–6. 9. Efficacy of low- dose estradiol vaginal tablets in the treatment of. Obstet Gynecol. 20. Transvaginal color Doppler sonographic assessment of uterus and ovaries in postmenopausal. Eur J Obstet Gynecol Reprod Biol. The effect of low dose micronized 1. J Clin Endocrinol Metab. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone. JAMA2. 00. 2; 2. 87: 2. The comparative effect on bone density, endometrium, and lipids of continuous. CHART Study): a randomized controlled trial. JAMA1. 99. 6; 2. 76: 1. The Writing Group for the PEPI Trial. JAMA1. 99. 5; 2. 73: 1. Menopausal symptoms and treatment- related effects of estrogen and progestin in. Women's Health Initiative. Obstet Gynecol. 20. Effects of estrogen and estrogen- progestin on mammographic parenchymal density. Effects of hormone replacement therapy on the mammary gland. Am J Obstet Gynecol. Vaginal bleeding in postmenopausal women taking low- dose norethindrone acetate and ethinyl. Obstet Gynecol. 20. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone. Fertil Steril. 20. Longitudinal patterns and correlates of hormone replacement therapy use. Am J Epidemiol. 19. Adherence to postmenopausal hormone therapy during the year after the initial prescription. Am J Obstet Gynecol. Estrogen- progestin replacement therapy and breast cancer risk: the Women's. Health Study (United States). Cancer Causes Control. Collaborative Group on Hormonal Factors in Breast Cancer. Breast density and parenchymal patterns as markers of breast cancer risk: a meta- analysis. Mammographic density as a surrogate marker for the effects of hormone therapy on risk of. Cancer Epidemiol Biomarkers Prev. Is mammographic density, as currently measured, a robust surrogate. Gynecol Endocrinol. Suppl 1): 1. 7–2. Breast cancer and hormone- replacement therapy in the Million Women Study. Lancet. 20. 03; 3. Hormone therapy and breast cancer risk. Climacteric. 20. 07; 1. Suppl 2): 5. 4–6. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol. 20. Neutral effect of ultra- low- dose continuous combined estradiol. Climacteric. 20. 07; 1. Risk of hospital admission for idiopathic venous thromboembolism among. Lancet. 19. 96; 3. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the. ESTHER study. Circulation. A prospective, observational study of postmenopausal. Ann Intern Med. 20. Postmenopausal hormone therapy and stroke: role of time since menopause and. Arch Intern Med. 20. Hendrix SL, Wassertheil- Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health. Initiative. Circulation. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 20. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Estrogen therapy and coronary- artery calcification. N Engl J Med. 20. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from. Arch Intern Med. 20. Long- term effects of transdermal and oral estrogens on. Maturitas. 19. 93; 1. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 20. Serum lipid profile improved by ultra- low doses of 1. Effects of E2 and E2/norgestimate hormone therapy on elevated baseline lipids. J Reprod Med. 20.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
September 2016
Categories |